The IV administration of the potent cr,-receptor ligand 4-phenyl-l-(4-phenylbutyl)piperidine (PPBP) provides neuroprotection against focal cerebral ischemia. We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal ischemia and reperfusion. Under controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 h of middle cerebral artery occlusion by the intraluminal occlusion technique. Sixty minutes after the onset of ischemia, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 km01 . kg-r . h-l) for 1,2,3, or 4 days or saline for 1 or 4 days. The infarction volume was assessed by triphenyltetrazolium chloride (TTC) staining on Day 4 after ischemia in all rats. The TTC-determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42 t-13 mm3; 10% ? 3% of ipsilateral hemisphere; P < 0.05) (mean ? SEM) compared with that in corresponding l-day control rats (124 2 22 mm; 29% t 5% of ipsilateral hemisphere; P < 0.05) or 4-day control rats (112 ? 10 mm; 26% ? 2% of ipsilateral hemisphere; P < 0.05). Cortical infarction volumes in 2-, 3-, and 4-day PPBP-treated rats were not different compared with l-and 4-day saline-treated controls. These data demonstrate that the a,-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the onset of focal ischemia but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection.
The IV administration of the potent cr,-receptor ligand 4-phenyl-l-(4-phenylbutyl)piperidine (PPBP) provides neuroprotection against focal cerebral ischemia. We tested the hypothesis that prolonged, continuous administration of PPBP would provide further neuroprotection in a rat model of transient focal ischemia and reperfusion. Under controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 h of middle cerebral artery occlusion by the intraluminal occlusion technique. Sixty minutes after the onset of ischemia, rats were randomly assigned to six treatment groups to receive a continuous IV infusion of PPBP (1 km01 . kg-r . h-l) for 1,2,3, or 4 days or saline for 1 or 4 days. The infarction volume was assessed by triphenyltetrazolium chloride (TTC) staining on Day 4 after ischemia in all rats. The TTC-determined infarction volume of the ipsilateral cerebral cortex was smaller in rats treated with PPBP for 1 day (42 t-13 mm3; 10% ? 3% of ipsilateral hemisphere; P < 0.05) (mean ? SEM) compared with that in corresponding l-day control rats (124 2 22 mm; 29% t 5% of ipsilateral hemisphere; P < 0.05) or 4-day control rats (112 ? 10 mm; 26% ? 2% of ipsilateral hemisphere; P < 0.05). Cortical infarction volumes in 2-, 3-, and 4-day PPBP-treated rats were not different compared with l-and 4-day saline-treated controls. These data demonstrate that the a,-receptor ligand PPBP attenuates ischemic injury when administration is initiated 60 min after the onset of focal ischemia but that prolonged continuous treatment with PPBP beyond 24 h provides no neuroprotection.
Implications: a-Ligands decrease infarction size in various animal models when given after the onset of stroke. Prolonged treatment with a potent cT-ligand is associated with loss of therapeutic efficacy for this compound. (Anesth Analg 1998; 87:1299-305) W e previously demonstrated that the acute administration of the potent and highly selective or-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) prevents early evidence of brain injury in rat (1) and cat models (2) 
Methods
The experimental protocol was approved by our animal care and use committee and conforms to the National Institutes of Health guidelines for the care and use of animals in research. Adult male Wistar rats weighing 260-340 g (n = 57) were anesthetized with halothane (l.O%-2.0%) in oxygen-enriched air (fraction of inspired 0, 0.35-0.40) to maintain the following conditions: arterial pH 7.35-7.40, Pace, 35-40 mm Hg, and Pao, loo-150 mm Hg. Using aseptic surgical techniques, cannulae were inserted into the right femoral artery and vein to monitor arterial blood pressure and arterial blood gases and to administer fluids and drugs. After cannulation, both catheters were exteriorized in the posterior midthorax. Rectal and temporalis muscle temperatures were monitored and maintained within a normothermic range with a heating lamp throughout the surgical procedures.
Cerebral perfusion was measured using laser Doppler flowmetry (LDF). An area 2-3 mm in diameter in the right parietal bone (2 mm posterior and 6 mm lateral to bregma) was thinned for placement of an LDF probe (Moor Instruments Ltd., UK) as previously described (13). To allow continuous monitoring of LDF, the head piece of the stereotaxic frame was modified to allow for free rotation around the longitudinal axis of the rat and was equipped with a snout mask for spontaneous ventilation and with a holder for the LDF probe. The probe was positioned over an area devoid of large cortical blood vessels, and its position was not changed throughout the experiment. The LDF signal was allowed to stabilize over a 30-min period before a baseline measurement was obtained before vascular occlusion. Transient focal ischemia (2 h) was produced by middle cerebral artery occlusion (MCAO) using an intraluminal suture technique as previously described (14), with some modification (1). Briefly, the right common carotid artery (CCA) was exposed through a lateral neck incision, and the external carotid artery (ECA) was ligated. The occipital artery branch of the ECA was coagulated, and the internal carotid artery (ICA) was carefully separated from the vagus nerve. The pterygopalatine artery was ligated with 4-O silk suture close to its origin. Ischemia was produced by advancing a 4-O monofilament nylon suture, with its distal tip rounded by application of heat, into the ICA through a puncture in the CCA until the LDF signal displayed a significant reduction. After placement, the intravascular suture was secured with a 6-O silk suture tied around the ICA. At the end of ischemia (2 h), reperfusion was produced by withdrawal of the string by 15 mm until the tip lay in the ICA; this was associated with rapid restoration of the LDF signal. Rats that did not demonstrate a significant reduction (to 40% of baseline) or rapid restoration of the LDF signal were excluded from the study. LDF measurements were obtained over 5-min periods at 5, 15, 30, 60, 90, and 120 min after MCAO.
At 1 h of MCAO, rats were randomly assigned to four treatment groups (n = 8 rats per group) and administered 1 kmol * kg-' * h-' PPBP in 20 mL of 0.9% saline (vehicle) by continuous IV infusion at a rate of 0.5 mL/h. The drug infusion was continued for 1, 2, 3, or 4 days. Control animals received the same volume of saline by continuous IV infusion at the same rate for 1 or 4 days (n = 8 rats each). Infusions were changed daily. In preliminary experiments, we found that the compound was stable in solution at room temperature for >24 h. At 15 min after the onset of reperfusion, rats were allowed to emerge from anesthesia and were given free access to food and water. On Day 4 after MCAO, rats were deeply anesthetized with 5% halothane and decapitated.
The brain was harvested and sliced into seven 2-mm coronal sections for staining with 1% triphenyltetrazolium chloride (TTC) in saline at 37°C for 30 min, as previously described (1). Infarction volume was measured using digital imaging and analysis software (SigmaScan Pro; Jandel, CA). The infarcted area (unstained) was numerically integrated across each section and over the entire ipsilateral hemisphere. Infarction volumes were measured separately in the cerebral cortex and caudoputamen and expressed as a percentage of the volume of the ipsilateral side.
A separate cohort of naive rats was treated with a continuous infusion of 0.9% saline (n = 3) or 1 pm01 * kg-r . h-l PPBP (M = 3) for 4 days. Rats were then killed and perfused with 10% neutral buffered formalin. The brains were embedded in paraffin and stained with hematoxylin and eosin. All values are expressed as means z SEM. Physiological variables were subjected to repeated-measures analysis of variance. Differences in infarction volume and mean residual LDF measurements among groups were determined by using one-way analysis of variance. Post hoc analysis was performed with the Newman-Keul's test. The criterion for statistical significance was P < 0.05.
Results
Mean arterial blood pressure (MAP), Pace,, Pao,, pH, and temporalis muscle temperatures were within normal physiological ranges in all groups at baseline (preischemia), during ischemia, and postischemia ( groups. During MCAO, the LDF signal was reduced by 71.6% -+ 1.2% from the baseline. The residual LDF during ischemia was similar in all groups (31% 2 2% in the l-day PPBP treatment group, 29% ? 3% in the 2-day group, 29% + 4% in the 3-day group, 27% + 4% in the 4-day group; 28% -C 3% in the l-day and 26% t 2% in the Cday saline-treated control groups). On withdrawal of the monofilament, laser Doppler cerebral blood flow returned rapidly to baseline values within 5 min in all groups. After 15 min of reperfusion, LDF was higher in saline-treated controls (140% 5 8% of baseline) than in PPBP-treated rats (90% + 6% of baseline) (Figure 1 ). The number of rats that died before the end of the experimental protocol was similar in the l-day PPBP treatment group (2 of lo), 2-day PPBP treatment group (3 of ll), and l-day saline control group (4 of 12). No rats died in the 3-or 4-day PPBP treatment groups or the 4-day saline treatment group. Cortical infarction volume measured at 4 days of reperfusion was smaller in l-day PPBP-treated rats (42 ? 13 mm"; 10% + 3% of ipsilateral hemisphere) than in l-day saline-treated controls (112 ? 10 mm3; 26% ? 2% of ipsilateral hemisphere) and 4-day saline-treated controls (124 + (Figure 2 ). There was no difference in cortical infarction volume measured at 4 days of reperfusion in the 2-, 3-, or 4-day PPBP-treated rats compared with the land 4-day saline-treated controls. There were no significant differences among groups for infarction volume in the caudoputamen (Figure 2) .
Histopathological examination of the brains using paraffin embedding, hematoxylin and eosin staining was similar in PPBP-treated and saline-treated rats, with no neuronal loss or morphological changes (Figure 3) . We confirmed the stability of PPBP in 0.9% saline for ~96 h at 37°C. Using high-performance liquid chromatography, we did not detect any foreign peaks, and the area under the peak remained constant.
Discussion
The main findings of this study are that in the focal ischemia (MCAO) with reperfusion model in the rat: a continuous l-day IV infusion of a potent a,-receptor ligand, PPBP, given 1 h after the onset of ischemia, Figure 2 . Infarction volume in the cerebral cortex and caudoputamen i n the six treatment groups. lD, 2D, 3D, 4D = l-, 2-, 3-, or 4-day 4-phenyl-1-(4-phenylbutyl)piperidine-treated rats, respectively; 1s and 4s = l-and 4-day saline-treated rats, respectively (n = 8 per group). *P < 0.05 versus l-and 4-day saline-treated control rats.
attenuates cortical infarction volume; and a prolonged, continuous infusion of PPBP beyond 1 day seems to offer no neuroprotection compared with vehicle controls.
Most previous studies on focal ischemic neuroprotection have used drugs that are given after the onset of ischemia as a bolus or a continuous infusion lasting ~4-5 h. Less is known about the effects of neuroprotective drugs given continuously over a several-day interval. PPBP penetrates the brain very readily when given IV with a slow in viva clearance from the brain (15). In our previous studies in both cats (2) and rats (l), PPBP ameliorated the effects of transient focal ischemia at the same dose used in the present study (1 pmol * kg-' * h-i). In the cat study, this neuroprotective effect could not be explained by either a more favorable redistribution of cerebral blood flow or an effect on brain temperature (1). Our previously reported study (2) demonstrated significant neuroprotection in the rat striatum, but not in the cortex, with the same dose of PPBP as used in the present study. However, in the study by Takahashi et al. (2), neurological examination (16) was used as a marker of ischemia after MCAO. Although neurological examination is a sensitive indicator of focal cerebral ischemia, successful reperfusion was an assumption in the study by Takahashi et al (2). In the present study, we used the LDF signal as a more objective and sensitive measure of MCAO and reperfusion; the criterion for successful MCAO was a reduction of LDF signal by at least 60% from the baseline. Previous studies in our laboratory (13) demonstrated that the consistency of infarction volume is correlated to the degree of LDF reduction during MCAO and to the adequate return of the LDF signal during reperfusion. Thus, we believe that the present study represents a more consistent model that allows for a better characterization than does neurological examination alone. In addition, we administered the PPBP for varying intervals after occlusion to determine whether its neuroprotective effect could be enhanced by prolonged administration.
Focal ischemic injury volume outcome is dependent on the temporal end point of the study. In the present study, we assessed infarction volume 4 days after MCAO. Although some investigators (17) have demonstrated that brain infarction after mild transient focal ischemia can develop in a delayed fashion (>3 days after the original insult), others have shown that cerebral edema can give an artifactual increase in infarction volume, as assessed by TTC staining. Lin et al. (18) found that edema was maximal 24 h after MCAO with a subsequent reduction at 3 days. The total volume of the infarcted cortex in the injured hemisphere was also smaller than the noninfarcted hemisphere 7 days after MCAO. Ongoing studies in our laboratory (unpublished data) demonstrate results similar to those of Lin et al. (18) . Thus, we believe that, in the model of focal cerebral ischemia used in this study, it is unlikely that infarction volume would be any larger than it was at 4 days.
The means by which a-receptors modulate ischemic neuronal injury is not completely understood. ISCHEMIA 1998; 87:1299-305 We can only speculate as to the mechanism for the decrease in neuroprotection afforded by prolonged PPBP administration.
One possibility is that prolonged PPBP administration causes neurotoxicity secondary to prolonged interaction with the NMDA receptor complex. Although glutamate-triggered events are central to excitotoxic neuronal injury (5,6), glutamate also subserves vitally important metabolic, neurotrophic, and neurotransmitter functions (25). Thus, suppression of glutamatergic function with both competitive and noncompetitive NMDA antagonists may also be deleterious (26). Likewise, the NMDA receptor knockout animal is a lethal clone (27). NMDA antagonist toxicity has been characterized as causing irreversible neuronal necrosis, especially in the rat cingulate cortex (26). Therefore, prolonged administration of PPBP may produce toxicity because it indirectly interferes with NMDA receptor function. However, in the present study, histopathological studies did not show any evidence of neuronal dropout or morphological changes between PPBP-and vehicle-treated rats. We specifically looked for morphological changes in the cingulate gyrus and the retrosplenial cerebral cortex. Thus, we can infer that the loss of ischemic neuroprotection observed with a prolonged continuous infusion of PPBP is not based on direct cytotoxic effects. However, we performed the histopathological studies in nonischemic animals, and it is therefore possible that the prolonged administration of PPBP after ischemia may exacerbate injury in the penumbral region.
The loss of neuroprotection with prolonged administration of PPBP may be a result of degradation of PPBP over time. However, we demonstrated the stability of PPBP in vehicle for 196 hours in vitro; little is known about the metabolism and pharmacokinetics of the drug in vim. Thus, it is plausible that PPBP breaks down into an inactive or toxic metabolite. We do not believe this to be the case because our previous studies, as well as the present study, afforded ischemic neuroprotection for 224 h. Temperature is an important variable and modulator in ischemic brain injury (28), and it is well established that temperature affects outcome and infarction volume in focal cerebral ischemia (29,30). Brain temperature is a more accurate variable in the assessment of ischemic neuronal injury. Small differences in brain temperature during and immediately after a period of transient focal ischemia can critically influence the neuropathological outcome (31-33). In the present study, rectal and temporalis muscle temperatures were monitored during preischemia, MCAO, and immediate reperfusion (Table 1) . Our group (l-3) and others (28) have demonstrated that a-receptor ligands afford neuroprotection without affecting body temperature. We attempted to control the temporalis muscle temperature during the acute experimental period, but we did not monitor temperature on a continuous basis beyond the immediate reperfusion period. Although we housed the animals in a warm environment, it is conceivable that variations in body and brain temperature could have affected infarction size in the experimental groups. In conclusion, this study demonstrates that a continuous IV infusion of the potent a,-receptor ligand, PPBP for 1 day attenuates cortical infarction volume in transient focal ischemia when given 1 h after the onset of ischemia. PPBP loses its neuroprotective action in focal ischemia when given continuously beyond 24 h.
